J.B. Chemicals & Pharmaceuticals Limited reported steady growth in FY26, with consolidated revenue from operations rising to Rs. 4,148 crore compared to Rs. 3,918 crore in FY25, while consolidated net profit increased to Rs. 709 crore from Rs. 660 crore a year earlier.

On a standalone basis, the company posted revenue from operations of Rs. 3,889 crore for FY26, up from Rs. 3,723 crore in FY25. Standalone net profit after tax rose to Rs. 674 crore from Rs. 653 crore in the previous fiscal.

For the quarter ended March 31, 2026, JB Pharma reported standalone revenue of Rs. 836 crore and net profit of Rs. 97 crore. Quarterly profitability was impacted by exceptional expenses of Rs. 27.18 crore, including severance compensation related to restructuring of the distribution network and additional gratuity liability arising from implementation of India’s new labour codes.

 The board of directors recommended a final dividend of Rs. 9.30 per equity share of Re. 1 each for FY26.